Advanced Filters
noise

Cary, North Carolina Clinical Trials

A listing of Cary, North Carolina clinical trials actively recruiting patient volunteers.

Found 82 clinical trials
B Basheerah Enahora, PhD

Ripe for Revival: Outcomes Evaluation of a Mobile Produce Market With Vouchers

Increasing access to healthy foods is crucial to combating chronic disease in rural communities. The Ripe for Revival mobile market, a non-profit eastern NC-based mobile market, seeks to improve healthy food access among those at greatest risk of food insecurity and poor health. By implementing vouchers at the mobile market, …

18 years of age All Phase N/A

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

This Study is a Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Obese or Overweight Subjects Without Diabetes Mellitus.

18 - 75 years of age All Phase 2

Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

This is a Phase 2, multi-site, double-masked, randomized, vehicle-controlled, study designed to evaluate the safety, tolerability, and efficacy in adult participants with DED.

18 years of age All Phase 2

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and …

30 years of age All Phase 3
E Emmanuel Lopez

CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 208-day study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evaluations (90 days).

12 - 35 years of age All Phase 1/2

Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With Moderate to Severe Plaque Psoriasis

Psoriasis is a skin disorder wherein skin cells multiply faster than normal, making the skin itchy and look patchy and red. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. The main objective of this study is to assess maternal, fetal, and infant …

years of age Female Phase N/A
L Lynn Jones

Registry of Older Patients With Cancer

RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.

65 years of age All Phase N/A
S Shakeel Chowdhry, MD

Stroke Thrombectomy and Aneurysm Registry

This international multi-center registry is used to collect existing information and outcomes for patients undergoing an operation for treatment of injuries to the brain including the blockage of blood flow to an area of the brain, an abnormal ballooning of an artery, abnormal tangling of blood vessels, abnormal formation of …

1 - 120 years of age All Phase N/A
T Taylor Fryman, BS

Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry

The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.

18 years of age All Phase N/A
A Amanda Chan

Late Onset Alzheimer's Disease

The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to participate.

55 years of age All Phase N/A

Simplify language using AI